Adcendo raises EUR 51 Million in Series A Financing led by Novo Holdings and Ysios Capital to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

by Ysios Capital

Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The ...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Buenavista provides €15.1 million for ...

by Buenavista Equity Partners

The funding will enable the development of infrastructure capable of a...

Photos Stream